Currently available first-line drug therapies for treating pancreatic cancer

Jennifer L. Olson, Richard J Bold

Research output: Contribution to journalReview article

Abstract

Introduction: Pancreatic adenocarcinoma is the 9th most common cancer in the United States and the 4th most common cause of cancer-related death given its poor prognosis. Areas covered: The authors have performed a literature search for pertinent published clinical trials, ongoing Phase 3 clinical trials, and current treatment guidelines using PubMed, Clinicaltrials.gov, and NCCN, ASCO, ESMO, and JPS websites. The review itself discusses landmark studies and ongoing research into the chemotherapy regimens recommended by each oncologic society. The authors also examine drugs that were promising but failed in Phase 3 trials and those currently being investigated. Finally, the authors provide their expert opinion on the subject and provide their future perspectives. Expert opinion: While advances in chemotherapy for pancreatic cancer have been limited in comparison to other cancers, there have been improvements in survival. Combination therapy and a goal of R0 resection are key elements to extend life. Novel agents directed at the unique properties of pancreatic cancer are promising.

Original languageEnglish (US)
Pages (from-to)1927-1940
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume19
Issue number17
DOIs
StatePublished - Nov 22 2018

Fingerprint

Pancreatic Neoplasms
Expert Testimony
Drug Therapy
Neoplasms
Phase III Clinical Trials
PubMed
Adenocarcinoma
Clinical Trials
Guidelines
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Capecitabine
  • chemotherapy
  • erlotinib
  • fluorouracil
  • FOLFIRINOX
  • gemcitabine
  • nab-paclitaxel
  • pancreatic cancer
  • S-1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Currently available first-line drug therapies for treating pancreatic cancer. / Olson, Jennifer L.; Bold, Richard J.

In: Expert Opinion on Pharmacotherapy, Vol. 19, No. 17, 22.11.2018, p. 1927-1940.

Research output: Contribution to journalReview article

@article{c74a5ec5a6894c8c9cc413e5278cac68,
title = "Currently available first-line drug therapies for treating pancreatic cancer",
abstract = "Introduction: Pancreatic adenocarcinoma is the 9th most common cancer in the United States and the 4th most common cause of cancer-related death given its poor prognosis. Areas covered: The authors have performed a literature search for pertinent published clinical trials, ongoing Phase 3 clinical trials, and current treatment guidelines using PubMed, Clinicaltrials.gov, and NCCN, ASCO, ESMO, and JPS websites. The review itself discusses landmark studies and ongoing research into the chemotherapy regimens recommended by each oncologic society. The authors also examine drugs that were promising but failed in Phase 3 trials and those currently being investigated. Finally, the authors provide their expert opinion on the subject and provide their future perspectives. Expert opinion: While advances in chemotherapy for pancreatic cancer have been limited in comparison to other cancers, there have been improvements in survival. Combination therapy and a goal of R0 resection are key elements to extend life. Novel agents directed at the unique properties of pancreatic cancer are promising.",
keywords = "Capecitabine, chemotherapy, erlotinib, fluorouracil, FOLFIRINOX, gemcitabine, nab-paclitaxel, pancreatic cancer, S-1",
author = "Olson, {Jennifer L.} and Bold, {Richard J}",
year = "2018",
month = "11",
day = "22",
doi = "10.1080/14656566.2018.1509954",
language = "English (US)",
volume = "19",
pages = "1927--1940",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "17",

}

TY - JOUR

T1 - Currently available first-line drug therapies for treating pancreatic cancer

AU - Olson, Jennifer L.

AU - Bold, Richard J

PY - 2018/11/22

Y1 - 2018/11/22

N2 - Introduction: Pancreatic adenocarcinoma is the 9th most common cancer in the United States and the 4th most common cause of cancer-related death given its poor prognosis. Areas covered: The authors have performed a literature search for pertinent published clinical trials, ongoing Phase 3 clinical trials, and current treatment guidelines using PubMed, Clinicaltrials.gov, and NCCN, ASCO, ESMO, and JPS websites. The review itself discusses landmark studies and ongoing research into the chemotherapy regimens recommended by each oncologic society. The authors also examine drugs that were promising but failed in Phase 3 trials and those currently being investigated. Finally, the authors provide their expert opinion on the subject and provide their future perspectives. Expert opinion: While advances in chemotherapy for pancreatic cancer have been limited in comparison to other cancers, there have been improvements in survival. Combination therapy and a goal of R0 resection are key elements to extend life. Novel agents directed at the unique properties of pancreatic cancer are promising.

AB - Introduction: Pancreatic adenocarcinoma is the 9th most common cancer in the United States and the 4th most common cause of cancer-related death given its poor prognosis. Areas covered: The authors have performed a literature search for pertinent published clinical trials, ongoing Phase 3 clinical trials, and current treatment guidelines using PubMed, Clinicaltrials.gov, and NCCN, ASCO, ESMO, and JPS websites. The review itself discusses landmark studies and ongoing research into the chemotherapy regimens recommended by each oncologic society. The authors also examine drugs that were promising but failed in Phase 3 trials and those currently being investigated. Finally, the authors provide their expert opinion on the subject and provide their future perspectives. Expert opinion: While advances in chemotherapy for pancreatic cancer have been limited in comparison to other cancers, there have been improvements in survival. Combination therapy and a goal of R0 resection are key elements to extend life. Novel agents directed at the unique properties of pancreatic cancer are promising.

KW - Capecitabine

KW - chemotherapy

KW - erlotinib

KW - fluorouracil

KW - FOLFIRINOX

KW - gemcitabine

KW - nab-paclitaxel

KW - pancreatic cancer

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=85058112639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058112639&partnerID=8YFLogxK

U2 - 10.1080/14656566.2018.1509954

DO - 10.1080/14656566.2018.1509954

M3 - Review article

C2 - 30325679

AN - SCOPUS:85058112639

VL - 19

SP - 1927

EP - 1940

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 17

ER -